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ENHANCED cGMP-DEPENDENT SIGNALING IN
ASTROCYTES: NOVEL THERAPEUTIC TARGET IN
ALZHEIMER’S DISEASE
Abstract
Over five million Americans suffer from Alzheimer’s Disease (AD), with an
expected 34% increase in the incidence in this disease over the next decade.
Unfortunately, there is no cure for AD. Recent studies have indicated that drugs

which increase the levels of cyclic guanosine-3’5’-monophosphate (cGMP) may

help preserve learning and memory in AD and enhance cognition in the aging

brain; however, the mechanism(s) of how cGMP exerts this beneficial effect is
unknown. The present findings now suggest that elevation of cGMP in
astrocytes depresses inhibitory potassium currents in these cells to stimulate

their protective influence on neuronal activity. Cellular currents were measured

directly in rat embryonic astrocytes via the perforated-patch whole-cell patchclamp technique, and these experiments demonstrated robust outward currents

due to potassium efflux. Currents exhibited slowly-activating, non-inactivating
kinetics, and were sensitive to inhibition by tetraethylammonium. Thus, these

currents were carried predominately by the delayed rectifier potassium (KDR)

channel, which is highly expressed in astrocytes. Stimulation of cGMP signaling

with sodium nitroprusside (a nitric oxide donor; 10mM; 10min) depressed

steady-state outward currents by an average of 34% (n=3). In other cells

addition of 8Br-cGMP (500mM; a membrane-permeable cGMP derivative) also
depressed these currents (18.4%, n=3). In contrast, neither SNP nor 8Br-cGMP

altered rapidly-inactivating, A-type potassium currents significantly. Lastly,
elevating cyclic adenosine-3’5’-monophosphate (cAMP) levels in astrocytes with

forskolin (10mM, 10 min) also depressed outward currents (17%; n=3). Taken

together, these findings suggest a novel cellular transduction mechanism that
could contribute to the beneficial effect of NO/cGMP signaling on learning and
memory: depression of KDR currents, which depolarizes astrocytes, and thereby

increases calcium influx via voltage-dependent (L-type) calcium channels.

Increased astrocytic calcium levels would in turn excite these cells and enhance
release of gliotransmitters to promote normal synaptic neurotransmission.
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1. INTRODUCTION
I.

Pathology and Pathological Diagnosis of Alzheimer’s Disease

Signs of AD include, but are not limited to, widening of sulci, shrinkage of

the gyri, the thinning of the cortical ribbon, ventricular dilation, atrophy of the
amygdala and hippocampus, significant loss of neurons, neutrophil threads,
granulovascular degeneration and amyloid angiopathy (Yaari et al., 2007).

Normally the brain of a patient with AD shows signs of atrophy in all areas

except the occipital portion (Yaari et al., 2007). Neuritic plaques and
neurofibrillary tangles are hallmark signs of AD, although they could be signs of
other neurodegenerative disorders such as dementia (Yaari et al., 2007).

Neuritic plaques are spherical in structure and consist of amyloid proteins
surrounded by atrophic neuritis (Yaari et al., 2007). There are two other

plaques that are seen in the brain of AD patients: “burnt out” and diffuse
plaques (Yaari et al., 2007). Diffuse plaques consist of unstructured amyloid

protein and “burnt out” plaques consist of dense core amyloid protein (Yaari et
al., 2007).

Amyloid protein consists of β-amyloid1-42, formulated from an

abnormal processing of the amyloid precursor protein (Yaari et al., 2007). βamyloid1-42 is toxic to the brain and considered critical to the pathogenesis of

AD due to the formation of insoluble clumps that lead to neuronal atrophy and
death (Yaari et al., 2007). Neurofibrillary tangles, also seen in the brain of AD
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patients, can also have devastating affects. Neurofibrillary tangles can cause

interference with the cytoskeleton structure of neurons, which ultimately

causes neuronal cell death (Yaari et al., 2007). Neurofibrillary and neuritic
plaques are not distributed evenly across the brain, but rather attack important
parts of the brain that effect specific neuronal systems (Yaari et al., 2007).

Pathological diagnosis of AD must meet certain criteria during

examination of the brain post mortem (Yaari et al., 2007). These criteria include

a significant number of neuritic plaques and neurofibrillary tangles (Yaari et al.,

2007). Small amounts of neuritic plaques and neurofibrillary tangles can be
found in clinically normal elderly persons. Therefore, a stricter guideline from

the National Institute on Aging-National Institute of Neurological and

Communicative Disorders (NIA-NINCDS) and Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) is deemed necessary for the

pathological diagnosis of AD (Mirra et al., 1993). Quantitative analysis of age-

adjusted densities and frequencies of plaques (given by NIA-NINCDS and
CERAD criteria), presence of neurofibrillary tangles and clinical diagnoses of
dementia are needed to diagnose AD pathologically (Mirra et al., 1993).
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II.

Clinical Diagnosis of Alzheimer’s Disease

There are two commonly used criteria and guidelines put forth that help

diagnose patients with AD: Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) and the National Institute of Neurological

and Communicative Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association (NINCDS-ADRDA) (McKhann et al., 1984). Clinical

cognitive decline presentation tends to be a precursor or sign of AD. In early
stages of AD, clinical features include, but are not limited to, short-term memory
loss, preservation of remote memory, some difficulty with word finding,

reduction in the ability to plan, judge, and organize and preserved social
behavior (Yaari et al., 2007). In the intermediate stages of AD, clinical features

include, but are not limited to, deterioration of logical reasoning, planning and

organizing, decline of remote memory, loss of day to day skills, delusions, visual
hallucinations, emotional distress and agitation, decrease in concern for

appearance and depression (Yaari et al., 2007). Late stages of clinical AD
consist of severe deterioration of all cognitive functions, inability to speak,
uncontrolled urinary and bowel systems, involuntary jerking and require

assistance with normal day-to-day activities (Yaari et al., 2007). Clinical
diagnosis of AD is usually determined by excluding other diseases and disorders
with the same clinical features such as manic-depressive disorder, Parkinson’s

disease, multi-infarct dementia, drug intoxication, thyroid disease, pernicious

anemia, luetic brain disease, subdural hematoma, occult hydrocephalus,
9

Huntington’s disease, Cruetzfeldt-Jakob disease and brain tumors (McKhann et
al., 1984)(Yaari et al., 2007). Exclusion is accomplished by using brain imaging,

objective neurological testing, neuropsychological testing, laboratory testing,
clinical examination and functional assessments (Yaari et al., 2007).

NINCDS-ARDA created the criterion for clinical diagnosis of AD to

address the substantial amount of cases diagnosed with AD that were found at

autopsy to have other conditions not AD related (McKhann et al., 1984). It was
important for the NINCDS-ARDA to create a uniform criterion for diagnosing AD
in order to develop a meaningful response to treatment (McKhann et al., 1984).

According to NINCDS-ARDA, there are three stages of clinical criteria of
diagnosis of AD: Probable, Possible, and Definite. The criteria for the clinical
diagnosis of Probable Alzheimer’s disease consists of diagnosis of dementia via
the

Mini-Mental

Test,

Blessed

Dementia

Scale

and

confirmed

by

neuropsychological tests, signs of deterioration in two or more cognitive areas,
progressive decline in memory and any other cognitive area, no disruption of

consciousness, age must be between 40 and 90, and exclusion of other possible

diseases or disorders that may be the cause of decline in the cognitive areas
aforementioned (McKhann et al., 1984). The criteria for the clinical diagnosis of
Possible Alzheimer’s disease can be made on the basis of dementia syndrome if

all other possible diseases or disorders are absent (McKhann et al., 1984).
Secondly, if there is a presence of a second systemic or brain disorder not

considered to be the cause of dementia then the patient can be diagnosed as
Possible (McKhann et al., 1984).

The criteria for the clinical diagnosis for
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Definite Alzheimer’s disease includes the clinical criteria for Probable
Alzheimer’s disease and histopathological evidence obtained post mortem.

Standard methods of examination via medical history, neurological tests,

psychiatric tests, clinical examinations, neuropsychological tests and laboratory
studies are needed to determine the clinical diagnosis stage of AD based on the
criteria provided by the NINCDS-ARDA (McKhann et al., 1984). Medical history
is taken to determine the progression of deterioration and to identify what

tasks the patient is no longer able to perform adequately (McKhann et al., 1984).

The medical history can also be taken from an individual that is familiar with
the routines of the affected patient to document changes in various functions
that the patient may not be aware of such as the inability to use money,

difficulty in dressing, reading and writing and the inability to recognize

previously familiar individuals (McKhann et al., 1984). Clinical examination is
used

to

document

symptoms

of

cognitive

impairment,

depression,

hallucinations, dementia via mini-Mental State Examinations or Blessed

Dementia Scales and impairment of sensory and motor systems (McKhann et al.,
1984). This complete examination allows the physician to exclude other
neurological disorders and disease. Neuropsychological testing is used to gain

additional information for a complete and thorough diagnosis of dementia, and
is valuable for determining the patterns and progression of impairment over a
period of time after therapies have been instituted (McKhann et al., 1984).

Specific laboratory tests are used to enhance diagnostic accuracy by identifying
other causes of dementia (McKhann et al., 1984).

There are currently no
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present laboratory tests that can diagnose AD during the life of the patient
(Yaari et al., 2007). It is known that AD patients tend to show increased slow-

wave activity that becomes more marked with the progression of the disease.

Electroencephalography is used to measure the wave activity of patients
believed to have AD, and is used as an electrophysiologic method to determine if
dementia is caused from depressive syndromes (McKhann et al., 1984).

Computerized tomography is used to exclude diseases and disorders such as
subdural hematoma, brain tumor, hydrocephalus, and dementia associated with
vascular disease to further aid in the diagnosis of AD (McKhann et al., 1984).

Regional cerebral blood flow (rCBF) measurements can be used to differentiate

dementia from AD (McKhann et al., 1984). A decreased measurement of
regional cerebral blood flow is seen in patients with Alzheimer’s disease
(McKhann et al., 1984). Quantitative assessment of the rate of glucose

utilization, oxygen consumption, and rCBF is assessed through positron
emission tomography and used to determine if the patient’s levels are

concurrent with encephalomalacia or AD (McKhann et al., 1984). Magnetic
Resonance Imaging is also an important laboratory test due to its ability to

reveal demarcations of gray and white matter which is helpful in delineating
differences between AD and multi-infarct dementia (McKhann et al., 1984).
Although laboratory test are not being used to diagnose AD, some markers and

histopathologic hallmarks related to neuritic plaques and neurofibrillary
tangles are used to improve diagnostic accuracy (Yaari et al., 2007).
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III.

Basic Function of Astrocytes

Astrocytes play a vital role in brain function, and are the major glial cell

population in the CNS (Brahmachari et al., 2006). Radial glial cells serve as the

precursor and direct descendants of astrocytes that formulate the grey matter

of the brain (Bushong et al., 2004). Astroglial syncytium is a physical integrated
network that connects adjacent astrocytic cells via gap junctions that allow

long-range signaling (Verkhratsky et al., 2010). Astrocytes are involved in
sending processes to blood vessels, in turn making up the neurovascular unit
which provides metabolic support in the brain (Verkhratsky et al., 2010).
Astrocytes also maintain cellular homeostasis of blood flow, extracellular fluid,

ions, transmitters, and regulation of synaptic function (Brahmachari et al.,

2006). Because of the multifunctional roles astrocytes play in neuronal
protection, it is likely that gaining a better understanding of astrocyte function

will lead to a clearer understanding of their role in Alzheimer’s disease – and as
a potential therapeutic target.

Astrocytes provide a metabolic connection between blood vessels and

the parenchyma of the brain, thus constituting a neurovascular unit

(Verkhratsky et al., 2010). There are two steps needed to maintain the
metabolic support of the neurovascular unit. First, astrocytes use neuronal
activity to regulate local blood flow, which is established by rapid vasodilation
after a local increase in neuronal firing (Verkhratsky et al., 2010). This

13

increased synaptic transmission causes astroglial Ca2+ signaling to trigger the

release of vasoactive substances (Ladecola et al., 2007). Secondly, astrocytes

provide metabolic substrates during increased glutamate release, which
activates Na+-dependent glutamate transporters (Verkhratsky et al., 2010). This

causes an increase in intracellular Na+ concentration in astrocytes triggering
glycolysis and lactate synthesis (Verkhratsky et al., 2010).

Extracellular ion concentration is extremely important in maintaining

brain function, and astrocytes play a major role in this process. Potassium ions

are one of the most important ions in considering homeostasis in the
extracellular space of the brain due to the large quantities released during

neuronal activity (Verkhratsky et al., 2010). Increased extracellular potassium
can depolarize the neuronal membrane, which alters excitability (Verkhratsky

et al., 2010). Astrocytes in the brain maintain homeostasis of extracellular
potassium concentrations through spatial K+ buffering (Kofuji et al., 2004).

When extracellular potassium concentrations are at a higher level than normal,

inward rectifying potassium channels provide an influx pathway for excess

extracellular K+ to reestablish normal extracellular concentrations (Verkhratsky

et al., 2010). Spatial K+ buffering is accomplished by the relocalizing of K+ ions

from regions of high K+ concentrations to regions of low K+ concentrations

within the local astrocytic network via astroglial water transport (Simard et al.,
2004).

Astrocytes are also important in neurotransmitter homeostasis in the

brain (Verkhratsky et al., 2010). Glutamate is the main excitatory
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neurotransmitter released into the extracellular space of the brain during

synaptic transmissions (Verkhratsky et al., 2010). Removal of glutamate is

important for preventing excitotoxicity and is taken up by perisynaptic
astrocytes (Swanson et al., 2005).

Non-toxic glutamine is formed from

glutamate after it is taken up by perisynaptic astrocytes and transported back to

the presynaptic terminal where it is converted back to glutamate for use in
synaptic transmission (Martinez-Hernandez et al., 1977 V39).

Astroglia’s role is to preserve the integrity of the host tissue following an

injury. Atrophic astrocytes are called reactive astrocytes (Ridet, J. et al., 1997).
Hypertrophy and proliferation of microglial cells and astrocytes are considered

reactive gliosis (Ridet, J. et al., 1997). Studies have shown that reactive gliosis

may prevent axonal regrowth but isolates CNS from further damage (Ridet, J. et
al., 1997). However, the pathology of reactive astrocytes in neurological
disorders remains far from being fully understood (Ridet, J. et al., 1997).
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IV.

The Role of Astrocytes in Alzheimer’s Disease

Alois Alzheimer discovered an abundance of glial cells in neuritic

plaques. Neuroglia plays a role in determining progression and outcome of most

neurological diseases (Verkhratsky et al., 2010). As discussed earlier, neuroglia
is important for homeostasis in brain function and any disruption in
homeostasis can be fatal for the nervous system.

Astroglia are normally

affected during the early stages of neurodegenerative disease, and may lie at the
core of initial disruption of neural circuitry in atrophic changes. Reactive

astrogliosis has become a hallmark of plaque-infested brains in the late stages
of AD (Nagele et al., 2003). Reactive astrogliosis is initiated by an increase in
the number of astrocytes due to the obliteration of local neurons from
neurodegenerative atrophy (Kofuji et al., 2003).

Increased astrogliosis has shown to have a correlation with increases in

cognitive decline (Simpson et al., 2010). Reactive astrogliosis in AD can be

initiated by β-amyloid peptide (AB) along with many other factors. Astrocyte

exposure to AB causes changes in Ca2+ signaling which contribute to astroglial

neurotoxicity (Abramov et al., 2003). Studies have shown that astrocytes within

AD-like conditions express BACE-1 (beta-site APP cleaving enzyme-1), which

gives the ability to produce AB (Rossner et al., 2005). Development of AB in the
brain of patients with AD requires two sequential cleavages of the APP (amyloid
precursor protein) done by BACE-1 (Jonsson et al., 2012).
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Studies show that patients in the early stages of AD are found to have

vascular impairments leading to a reduction in blood flow (Bell et al., 2009).

Astrocytes play a major part in the neurovascular unit controlling the link

between neuronal activity and local blood flow through several signaling
cascades. In AD, the neurovascular unit is a potential target of dysfunction
because of the presence of brain capillaries within AB plaques, which affects

microcirculation and vascular AB clearance (Bell et al., 2009). Astrocytes
control excess blood flow (hyperemia) and local cerebral circulation, which is

important in functional activity of neural networks (Verkhratsky et al., 2010).

Atrophic astrocytes may cause dysfunction of the neurovascular unit; however,

the mechanism remains unclear in AD.

Early stages of AD in humans are characterized by a significant decrease

in glucose use, thus causing a metabolic remodeling of astroglia in AD

(Verkhratsky et al., 2010). Studies show that AB causes this remodeling by

increasing reactive oxygen species production in astrocytes (Verkhratsky et al.,
2010). However, the glucose metabolic pathways in AB cultured astrocytes are

not fully understood. There are many discrepancies amongst studies that show

an increase and decrease in the activity of enzymes associated with glucose

metabolism, which may be due to cell-specific changes in glucose metabolism
developing at different stages of AD.

Atrophic astrocytes causes reduced synaptic coverage, dysfunction of

neurovascular unit, reduced functional hyperemia, reduced metabolic support,
and altered extracellular homeostasis of ions and neurotransmitters which can
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be the source of reduced synaptic connectivity through synaptic malfunction

leading to cognitive decline in early stages of AD (Verkhratsky et al., 2010). AB

plaque causing reactive astrogliosis leads to the release of inflammatory and

neurotoxic factors, which impairs homeostatic function (Verkhratsky et al.,
2010). Dysfunction of normal homeostatic brain function leads to neuronal

death, and causes cognitive decline and atrophy of the brain in the late stages of
AD.
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V.

Glial Fibrillary Acidic Protein Expression in Astrocytes

As mentioned above, reactive astrocytes may play a key role in

Alzheimer’s disease and many other neurodegenerative diseases. The secretion

of neurotrophic factors in astrocytes is used for neuronal survival, but the rapid
overexpression of these factors ultimately leads to neuronal death and brain

injury (Brahmachari et al., 2006). Glial fibrillary acidic protein (GFAP) is one of
the many factors expressed in astrocytes, and is localized to astrocytes in the

brain based on immunofluorescence and histological studies (Bignami et al.,

1977). GFAP is often used as a tool to monitor development and locate reactive
astrocytes within the brain via staining techniques in vitro and in vivo

(Morrison et al., 1985). Studies have shown that when astrocytes become
reactive, there is an increased expression of GFAP (Brahmachari et al., 2006).

Studies also show that Alzheimer’s pathologic hallmarks, senile plaques, are
linked with GFAP-positive reactive astrocytes (Brahmachari et al., 2006). The

increased levels of GFAP are synonymous with the severity levels of astrogliosis

(Brahmachari et al., 2006). However, there is no evidence that supports the

actual mechanism that shows how increased astroglial expression of GFAP
affects neurodegenerative disease (Brahmachari et al., 2006).
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VI.

Function of K+ Channels in Potassium Spatial Buffering

Regulation of extracellular potassium concentration is extremely

important for proper neuronal function (Bay et al., 2012). Potassium efflux

occurs from axons during action potential propagation causing an increase in
extracellular potassium concentration (Somjen et al., 2001).

Uncontrolled

increase of K+ extracellular space can lead to the disruption of neuronal activity

(Chever et al., 2010). The regulation of extracellular potassium concentration at

synaptic sites is controlled by a mechanism referred to as potassium spatial
buffering or potassium siphoning (Kofuji et al., 2004). The membrane potential
of astrocytes at high neuronal activity is negative to the potassium Nernst

potential causing a driving force to influx extracellular potassium ions
(D’Ambrosio et al., 2002). Extracellular potassium ions in the brain flow

through potassium inward rectifying channels (Kir), more specifically the Kir4.1
channel, resulting in potassium clearance (Bay et al., 2012). Once the uptake of
potassium has occurred, the potassium is then redistributed to other astrocytes

with low potassium activity via gap junction coupling or indirect coupling of
astrocytes (D’Ambrosio et al., 2002). Glial cells are considered to have a high
conductance of potassium ions (Higashi et al., 2001).

Kir channels consist of two membrane domains, M1 and M2, and a

conserved pore segment subunit containing H5. (Abraham et al., 1999). The H5
segment of the pore and M2 subunit of the membrane are essential for
20

potassium diffusion (Abraham et al., 1999). Kir channels’ hallmark is inward
rectification in the current-voltage relationship that limits potassium efflux at
depolarizing membrane potentials (Nichols et al., 1997).

Kir channels are

essential in potassium homeostasis that control resting membrane potential
and coupling of the metabolic cellular state during membrane excitability (Jan

et al., 1997). Kir channels have seven subfamilies, Kir 1.0 to Kir 7.0, with subsets
within the subfamilies.

Kir4.1 is the subset of Kir 4.0 subfamily and the only Kir channel

expressed in neuronal astrocytes (Higashi et al., 2001) (Hibino et al., 2004).

Studies also show that Kir4.1 is essential in potassium buffering in astroglia
cells (Djukic et al., 2007). Knock out of Kir 4.1 has shown to cause severe

pathology, early postnatal lethality, severe depolarization of glia cells, and
impairment of astrocyte potassium and glutamate uptake. Loss of function of
Kir 4.1 can cause tumor progression and astrogliosis (Zurolo et al., 2012).

If extracellular concentration of potassium is not controlled, it can cause

neuronal injury (Bay et al., 2012). Increased extracellular concentration of

potassium has shown to effect neuronal excitability therefore impairing
neuronal function (Djukic et al., 2007). Exposure to elevated potassium efflux
can reduce neuronal firing due to depolarization-induced inactivation of sodium

channels, which decreases transmitter release (Djukic et al., 2007). Studies have

shown that impairment of potassium uptake can prevent long-term depression
maintenance in the hippocampus due to increased synaptic activity during
neuronal potentiation (Djukic et al., 2007). This reduction in clearance of
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potassium in extracellular space causes an accumulation of potassium ions,
which leads to synaptic augmentation (Djukic et al., 2007). Elevated levels of
potassium in extracellular space can cause depolarization, which can lead to

increased glutamate release from pre-synaptic cells and enhanced activation of
NMDA receptors in post-synaptic cells causing a decrease in neuronal
spontaneous activity (Djukic et al., 2007).
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VII.

NOS/NO

Nitric oxide (NO) is produced by nitric oxide synthase (NOS) using L-

arginine as its substrate (Urzula et al., 2010). There are three isoforms of NOS;
neuronal nitric oxide synthase (nNOS), endothelial nitric oxide synthase (eNOS),

and inducible nitric oxide (iNOS) (Urzula et al., 2010). All CNS cells have the

ability to synthesize NO (Lincoln et al., 1997). NO carries no charge making it

relatively unreactive, which allows it to freely move across membranes without
being destroyed before reaching its target (Urzula et al., 2010). NO is a free

radical with a short half-life. Although NO is relatively unreactive in its steady
state, in the presence O2- it is readily reactive, which forms cytotoxic

peroxynitrite anion (ONOO-) (Urzula et al., 2010). This formation of ONOO- is

extremely toxic and damaging to the cell. Astrocytes however, have the ability
to make NO without detriment to the cell. Low nanomolar concentrations of NO
can cause synthesis of cGMP. NO synthesis is disrupted under pathological

conditions, which alters cGMP concentrations (Dawson et al., 1996). Studies
suggest that NO synthesis is altered in the senescent brain (Law et al., 2002).

Scientists believe that NOS plays a role in memory improvement in older

animals and is an integral part in the NO/cGMP signaling pathway. Studies

show increased NOS activity in the aged dentate gyrus of the hippocampus in
the senescent brain when compared to younger brains of rats (Chalimoniuk et

al., 1998).

Researchers argue that NO regulates hippocampal processes

generated during spatial learning (Urzula et al., 2010). Evidence suggests that
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β−amyloid activates NOS (Colton et al., 2002). iNOS has also been present in
neurofibrillary tangles within neurons (Colton et al., 2002). NOS isoform
expression is increased in Alzheimer’s disease and may cause oxidative damage

and may trigger the activation of intracellular signaling that perpetuates the
process of neurodegeneration, ultimately causing cell death (Luth et al., 2001).

Even though NO has some neuroprotective features, it has been

implicated in the pathogenesis of neurological disorders, such as Alzheimer’s

disease, Parkinson’s disease, multiple sclerosis, ischaemia, and amyotrophic
lateral sclerosis (Heales et al., 1999).
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VIII.

cGMP/ PKG (cGMP-dependent protein Kinase)

Memory is a phenomenon that is made up of acquisition, consolidation

and retrieval processes (Bollen et al., 2014). Consolidation is the process of
stabilizing and storing newly acquired information (Kandel et al., 2001).

Molecular transformations at participating synapses are responsible for

consolidation. cGMP is known to play a role in early memory consolidation and
in specific neuroplasticity of long-term potentiation (LTP) (Bach et al., 1999).

Studies suggest that improved memory formation is due to the enhanced cGMP

cascades via de novo protein synthesis (Lu et al., 2002). This action indicates
that cGMP and PKG are in concert, which may facilitate memory formation.

In the 1970’s, cGMP and PKG were the topic of research in a small

number of laboratories.

Much research was done to determine how this

signaling system was activated, what biological processes it regulated, and what
role substrates of PKG played in the cellular system. In recent years, PKG has

played a major role in two pathways that contribute to smooth muscle
relaxation.

Atrial natriuretic peptide (ANP), nitric oxide (NO) and carbon

monoxide are signaling agents that lead to increased concentrations of cGMP

through the activation of guanylate cyclase (Wang et al., 1997). Recent studies

have shown that these signaling pathways may play a role in neuronal function

and more importantly a possible therapeutic target for Alzheimer’s disease.
Researchers have found that the signaling pathway for cGMP may control
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mediation or modulation of neurotransmitter release and uptake, neuronal
differentiation and gene expression, learning and memory, brain seizure
activity, and neurotoxicity (Garthwaite et al., 1995). cGMP regulates cGMP-

gated ion channels, PKG, and some subtypes of phosphodiesterases (Hoffman et
al., 1992). PKG phosphorylates its substrates when activated by cGMP mediated

signal transduction (Matsumoto et al., 2006). However, there is little known
regarding the downstream signaling events after increased intracellular

concentrations of cGMP in the nervous system. In this study we aim to provide

evidence that will clarify the downstream signaling events during elevated
cGMP that may lead to a better understanding of this cascade in the nervous
system, more specifically in astrocytes.

Recent studies have shown that PKG does play a role in certain neuronal

events resulting from elevated cGMP levels. Studies have showed that PKG plays

a direct role in the increasing of neuronal Ca+ currents, neurotransmitter

release, the activation of neuronal K+ channels, and the presynaptic target for

the retrograde messenger in LTP; leading scientists to believe that PKG plays an

essential role in regulating cGMP signaling in the nervous system (Wang et al.,
1997).

There are two types of PKG, type I (PKG-I) and type II (PKG-II) (Hoffman

et al., 1992). PKG-I has two variants Iα and IIβ. PKG-I has been prevalent in the

plasma membrane, Golgi structures, endoplasmic reticulum, and nucleus in

various cells (Pryzwansky et al., 1995). PKG-I is also expressed in the cerebrum
and cerebellum (Schlichter et al., 1982). However, cerebellar expression of PKG-
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I is 20-40 times higher that that found in the cerebrum leading some scientists

to question the specificity of PKG localization outside the cerebellum (Schlichter
et al., 1982). It has been determined that non-cerebellar PKG is derived from

tissue vascularization (Schlichter et al., 1982). Initial studies showed that PKG-II

mRNA was detected in the cerebrum at higher levels than in the cerebellum

(Uhler et al., 1993). PKG-II is mostly found in the thalamus, cortex, septum,
amygdala, and olfactory bulb (El-Husseini et al., 1995). Very little levels were

seen in the hippocampus and striatum (Wang et al., 1997). However, increased
levels of PKG-I were found in the hippocampus and striatum as compared with
PKG-II, suggesting that PKG-I may be the specific variant in the downstream

signaling cascade of cGMP during improved memory and learning (Wang et al.,

1997).

Although PKG is closely related to the cAMP-dependent protein kinase

(PKA), the substrate specificity of these two kinases remains misunderstood.

Studies show that there are not many PKG substrates and the only one found to
be relatively specific for PKG is G substrate (Walaas et al., 1983).

Studies have

also shown that the function of PKG substrates can be grouped into the

following six categories relating to signal transduction: 1) cyclic nucleotide
action, 2) protein phosphatase regulation, 3) cytoskeletal dynamics, 4)
intracellular calcium homeostasis, 5) ion channel regulation, and 6) GTPbinding proteins (Wang et al., 1997).

cGMP and PKG signaling can functionally regulate ion channels,

specifically potassium, chloride, and sodium channels due to their influence in
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regulating neuronal function (Wang et al., 1997). cGMP activates PKG, which
causes Ca+2 activated K+ channels to open causing efflux of K+ ions resulting in
hyperpolarization and inhibiting voltage-gated calcium channels (Wang et al.,

1997). This mechanism is seen in the vasculature and also in rat pituitary
tumor cells.

The downstream signaling mechanisms of how cGMP and PKG modulate

ion channel function in astrocytes is poorly understood, therefore additional
studies are needed to clarify this mechanism.

NO-stimulated cGMP

accumulation can enhance PKG activity in neurons and nerve terminals making
it an extremely important piece to the puzzle. It is important to map out a
working mechanism that fully explains the NO/cGMP-PKG signaling pathway in

the CNS as a possible novel therapeutic target for memory and cognition
disorders. Future studies will be needed to gather a better understanding of

PKG substrates and their functionality in this pathway and its contribution to
neurotransmission mediated by cGMP.
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IX.

NO/cGMP/PKG Pathway

Smooth muscle relaxation, platelet aggregation and disaggregation,

neurotransmission, long term potentiation, and depression are all examples of
signal transduction by way of the NO/cGMP pathway (Warner et al., 1994). NO

was previously understood as a pollutant only due to its physical properties

however, through further understanding NO can also be seen as a signaling
agent (Denniger et al., 1999). NO is an excellent ligand for heme, which allows it

to bind to sGC at low concentrations and effective for signal transduction of

several pathways in the cardiovascular and nervous system (Denniger et al.,
1999).

Nitric Oxide (NO) is a stimulator of soluble guanylate cyclase (sGC), the

only proven receptor for NO. (Denniger et al., 1999). sGC catalyzes the

conversion of guanosine 5’ triphosphate (GTP) to cyclic guanosine 3’,5’monophosphate (cGMP) (Denniger et al., 1999). sGC is a heterodimeric protein

where NO binds to the sGC heme, which activates the enzyme, thus increasing
cGMP levels (Denniger et al., 1999). This rise in cGMP allows sGC to send a NO

signal to the downstream elements of the signaling cascade-cGMP-dependent

protein kinase (PKG), cGMP-gated cation channels and cGMP-regulated

phosphodiesterase (PDE). PKG phosphorylates target proteins in response to
increased cGMP production (Lohmann et al., 1997). PDE’s hydrolyze cGMP to

GMP (Denniger et al., 1999). cGMP-gated cation channels open in response to
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increased concentrations of

cGMP (Denniger et al., 1999). This signaling

pathway is intimately involved in the regulation of vascular tone and platelet

function. (Denniger et al., 1999). This pathway is also involved most notably in
the neurotransmission, long-term potentiation (LTP), and depression within the

nervous system. Recently cGMP and PDE inhibitors have been the topic of
fervor as of late because of its positive effects on improving memory and
learning.

Higher concentrations of cGMP are found in the brain more than any

other peripheral organ (Urzula et al., 2010). Aging of the brain causes decreases

in cGMP concentrations (Denniger et al., 1999). Activation of sGC and

degradation by PDE’s are the regulators of the concentration of cGMP (Denniger
et al., 1999). Observed decreases in cGMP concentration in the aged brain has
been directly linked to lower synaptic plasticity and cognitive performance

(Denniger et al., 1999). PDE inhibitors have also shown to improve learning and
memory in older rats.

Understanding whether sGC’s expression or activity is altered by the

aging process is extremely important in understanding NO/cGMP pathway’s
involvement in age-related brain disorders. We understand that NO/cGMP
signaling pathway is deeply involved in regulating brain function. sGC level may

be a major influence to age-related brain disorders. Researchers determined

that cGMP levels were significantly higher in the presence of PDE inhibitors in
the aged-brain, leading scientist to believe sGC is active and not the cause of

cognitive decline in the senescent brain (Denniger et al., 1999). On the other
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hand inhibition of sGC blocked memory formation. Studies have shown that

decline in cGMP in the aged-brain may be a causative factor in cognitive decline

in the senescent brain (Puzzo et al., 2006). Increases in PDE expression and

activity have shown to decrease cGMP concentration due to hydrolysis of cGMP
to GMP in the aged-brain (Denniger et al., 1999). Studies suggest that

administration of PDE inhibitors improves object memory and increases NOS
activity in the hippocampus of aged rat brains (Denniger et al., 1999). Studies

have also shown that when animals induced with PDE inhibitors PKG had no

effect on NOS activity, which suggests that PKG is independent of NOS activity
(Denniger et al., 1999). These data suggests that PDE inhibitors could improve
cognitive and memory loss performance via NO/cGMP signaling pathway in the
senescent brain.

Figure 2-1

(Urszula et al., 2009)
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X.

Role of the NO/cGMP pathway in LTP

Studies have shown that LTP involves the activation of postsynaptic

glutamanergic NMDA receptors, which is followed by an increase in calcium
flow in neurons (Puzzo et al., 2006). Understanding the importance of the role

of the NO/cGMP pathway in LTP in neurons can help us create a better
foundation of the role this signaling pathway plays in astrocytes and its possible
role in improving cognitive function.

Studies show that NOS inhibitors block LTP, which suggests that

NO/cGMP pathway is extremely important in the LTP process (O’Dell et al.,

1991). Large amounts of glutamate are released during LTP at the presynaptic

terminals suggesting that the induction of LTP involves the production and
release of NO from the postsynaptic dendrites (O’Dell et al., 1991). So given that

the signaling agent NO generates cGMP, cGMP is posed to produce potentiation.
Studies show that exogenous cGMP can bypass the postsynaptic events of the
induction of LTP and be injected into the presynaptic neuron to produce LTP
(Haley et al., 1992).

Behavioral studies have demonstrated that NO is likely to be involved in

some types of learning and memory. Blocking NO via NOS inhibitor impaired

spatial learning, olfactory memory, short-term memory, and long-term memory

(Boheme et al.,1993). Scientist believe that NO’s effect on memory is mediated
through the NO/cGMP pathway (Puzzo et al., 2006).
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The molecular events that encompass the NO/cGMP signaling pathway

in the aging brain are of great interest to researchers as a possible therapeutic

target in neurological disorders in which cognitive function declines. The ability

of PDE inhibitors to restore cGMP levels, which induces calcium influx through

cGMP-gated ion channels to improve cognitive performance, is a step in the

right direction (Denniger et al., 1999). The molecular mechanism for why cGMP

metabolism via PDE inhibitors restores cognitive function and improving
memory has yet to be determined.
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XI.

NO/cGMP Signaling Pathway in Alzheimer’s Disease

Studies have shown that Aβ peptide inhibits activation of the

NO/cGMP/cAMP pathway during hippocampal synaptic plasticity (Denniger et

al., 1999). Studies have also showed that NO/cGMP pathway plays a protective
role in apoptosis induced by Aβ (Puzzo et al., 2006). On the other hand
excessive production of NO causes neuropathology (Denniger et al., 1999).

Finding the right balance in NOS production and availability without causing

neurotoxicity can limit neuropathology and increase neuroprotection. This

suggests that improving NO/cGMP signaling could also prove to be a novel
therapeutic target for Alzheimer’s disease.

Wirtz-Brugger revealed that Aβ induced apoptosis can be suppressed by

NO donors, cGMP analogs, and PDE inhibitors (Wirtz-Brugger et al., 1993).

Aβ also reduced production of eNOS has also been found to be a risk factor for

Alzheimer’s disease (McCarty et el., 1998). Induction of Aβ causes decreased

production of NO because of the lack of eNOS phosphorylation (Paris et al.,
1999). Aβ induced vasoconstriction can be blocked by PDE inhibition, which in

turns increases cGMP levels preventing Aβ microglial inflammation and exerts a
neuroprotective action via amyloid precursor protein (APP) (Paris et al., 2000,
Mattson et al., 1999).

NO has also been linked with neurotoxicity in Alzheimer’s disease.

Studies have shown that Aβ increases the production of NO (Tran et al., 2001).
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iNOS inhibitors were used as a treatment to improve spatial memory in

Aβ infused rats (Haas et al., 2002). Studies showed that iNOS was increased
when Aβ is increased in glial cells (Haas et al., 2002). In the microglia

Aβ activates the synthesis of NO, causing neurotoxicity (Xie et al., 2002). This

neurotoxicity is blocked when inhibitors of NO synthesis and catalysts of
peroxynitrite decomposition are introduced to Aβ induced activated microglia
in Alzheimer’s disease (Xie et l., 2002).

Aβ decreases sGC expression in brain astroglial cells reducing cGMP

production in patients with Alzheimer’s disease (Baltrons et al., 2002).

Stimulating sGC increases cGMP levels and can reestablish normal synaptic

plasticity following its block by Aβ (Puzzo et al., 2006). Τhis was confirmed by
experiments in which 8-Br-cGMP, a membrane-permeable cGMP analogue,

reversed the inhibition of LTP caused by Aβ (Puzzo et al., 2006). Increases in

cGMP were found to reduce Aβ-induced cell death (Walsh et al., 2000). Findings
suggest that KT5823, a PKG inhibitor, blocked the beneficial effect of cGMP

analog 8-Br-cGMP (Puzzo et al., 2006). This lead researchers to believe that
Aβ−induced LTP impairment is likely mediated through the activation of PKG

(Puzzo et al., 2006). Cyclic AMP response protein (CREB) phosphorylation, a

transcriptional factor, is a consequence of PKG activation that is involved in

memory and learning (Bourtchuladze et al., 1994). Aβ blocks the increase of

CREB phosphorylation during synaptic plasticity (Tong et al., 2001). Increasing
cGMP to normal levels causes CREB phosphorylation to be reestablished.

Inhibition of any of the components of NO/cGMP/PKG pathway suppresses
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CREB phosphorylation (Puzzo et al., 2006). CREB phosphorylation and LTP is

specifically mediated through PKG because treatment with an inhibitor of PKA
did not overturn the positive effects of cGMP analogues (Puzzo et al., 2006).

Acetycholinesterase inhibitors, a common therapy for AD, have limited

efficacy in improving learning and memory. Researchers are trying to find a
way to inhibit the formation of neurofibrillary tangles, decrease Aβ load in the

brain by use of agents that inhibit Aβ oligomerization, inhibit inflammation and
oxidative damage, or by use of immunizations that remove Aβ from the brain all

together. However there has been no way to implement these strategies in
normal physiological conditions effectively and safely. However, drugs focusing

on the NO cascade can possibly be an effective way to counteract the
progression of Alzheimer’s disease by acting at a level downstream of

Aβ production. Results have shown that drugs that up-regulate NO can be used

as a prophylactic measure to not only offset cognitive impairment and the
inhibitory effects of Aβ, but also delay the natural progression of the disease.

Gaining a fundamental understanding how molecular components of
Alzheimer’s disease affects NO/cGMP/PKG signaling cascade will be
instrumental in improving upon current research.
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XII.

Phosphodiesterase (PDE)/ PDE Inhibitors)

Decline in cognitive function has been one of the many problems that

arise as people age. Cognitive decline is also seen as a symptom in many

neuropathological conditions such as Alzheimer’s disease. A considerable
amount of research has been done to combat cognitive decline however there is

still a great need for drugs that counteract this deterioration. There has been an
increase in interest in drugs that inhibit phosphodiesterase enzyme (PDE).

Studies show that inhibiting PDE improves cognitive performance in animals
and in man.

PDE’s are enzymes that play a role in the NO/cGMP/PKG signaling

pathway by hydrolyzing cGMP or cAMP into their respective inactive form
throughout the body. There are 11 gene-related families of isozymes that
encompass the PDE family, PDE 1- PDE 11 (Heckman et al., 2015). They are

distinguished based on their affinity for cAMP and cGMP (Heckman et al., 2015).

There is a strong interest in PDE 2 due to its high expression in the limbic
system and the adrenal cortex (Xu et al., 2015). These specific areas are

associated with cognitive function and regulation (Xu. et al., 2015). There has
also been interest in PDE 3, PDE 5, PDE 6 and PDE 9 due to the high affinity for
cGMP (Heckman et al., 2015).
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PDE inhibitors (PDE-Is) have been of interest because of its positive

effects on cognitive function when used as a therapeutic application. Impaired
memory function is linked to several neurological brain disorders. PDE-Is are

being used to target cognitive domains in the brain (Bollen et al., 2014). PDEs

are found to be in abundance in the brain particularly in the thalamus, striatum,
and prefrontal cortex (Bollen et al., 2014).

Some argue that PDE-Is induced

cognition enhancement is the result of increased blood flow due to PDE-Is being

a vasodilator (Bollen et al., 2014). Studies suggest that PDE-Is, such as

vardenafil, sildenafil, and rolipram, did enhance memory performance but did
not increase blood flow in the hippocampal areas disputing earlier notions
about vasodilation (Bollen et al., 2014).

PDE-Is ability for memory

improvement is dependent on PKG (Matsumoto et al., 2006). cGMP-PKG

signaling causes Ca2+ influx, because of the lowered stimulation threshold for
Ca2+, therefore enhancing postsynaptic signaling (Bollen et al., 2014). This

mechanism is thought to be the underlying effector of long-term plasticity in

LTP and memory formation.

PDE-Is therapeutic use has important implications in furthering the

potential treatment plan in a wide array of disorders involving cognitive

decline. Although PDE-Is have pro-cognitive effects their therapeutic use is
hindered due to their adverse side effects. Studies do show that lower dose
treatment of cGMP specific PDE-Is and dual substrate PDE-Is prove to be a more

viable option over singular PDE inhibition treatment (Bollen et al., 2014).
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Further studies are needed to determine if this treatment plan will be effective
clinically.
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XIII. Potassium Channel Expression in Embryonic Rat Neural Progenitor
Cells

Rat neural progenitor cells differentiate into neurons, astrocytes, and

oligendrocytes. Two types of voltage-activated K+ currents, non-inactivating

delayed rectifier and fast inactivating A-type, have been recorded in neural
progenitor cells (Liebau et al., 2006). It is known that voltage gated K+ channels
currents are most notably seen in the development of the nervous system

(Smith et al., 2008). Some tetrodotoxin sensitive Na+ currents were seen in low
density, but were insufficient to generate action potentials (Sah et al., 1997).

Major current expressions seen during electrophysiological tests in progenitor
cells are mostly potassium channels (Smith et al., 2008). cDNA microanalysis of

embryonic rat neural progenitor cells revealed that three Na+ and thirteen K+
genes were found (Cai et al., 2003). These genes encoded a delayed rectifier,
inward rectifying, and Ca+ sensitive K+ channels (Smith et al., 2008).

Whole-cell recordings of embryonic neural progenitor cells revealed

robust outward currents comprised predominately of delayed rectifier and an

A-type K+ channels (Smith et al., 2008). No inward currents were detected
during whole cell recordings of rat embryonic neural progenitor cells (Smith et

al., 2008). Due to the minimal detection of Na+ currents one can assume that

embryonic neural progenitor cells are incapable of generating action potentials

(Smith et al., 2008).

Although little electrophysiology has been done on

embryonic astrocytes, studies done on embryonic neural progenitor cells
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provide a good source of background information that proved beneficial in our
research.
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XIV.

Function of Voltage-Gated Ca2+ Channels in Astrocytes

Studies have shown that Ca2+ in astrocytes can modulate neuronal

activity (Hayden et al., 2001). Synaptic activity causes neurotransmitter
receptor activation, which in turns increases intracellular Ca2+ in astrocytes

causing excitability (Poter et al., 1996).

Extracellular accumulation of K+

depolarizes astrocytes to induce Ca2+ influx via voltage-gated Ca2+ channels
(Duffy et al., 1996). Astrocytes modulate synaptic transmission due to

glutamate release via Ca2+ and SNARE protein-dependent exocytosis (Araque et
al., 2000). Mechanisms of how Ca2+-dependent release of glutamate from

astrocytes remain unclear.

Voltage-gated Ca2+ channels are classified into two properties, low-(T-

type) and high (L-,N-,P-, Q-, and R- type) voltage-gated Ca2+ channels (Tsien et

al., 1988). High voltage-gated Ca2+ channels consist of different α1 subunits,

which form the ion conducting pore, selectivity filter, voltage sensors, and
interaction sites for Ca2+ blockers and activators (Hoffman et al., 1999). Other

auxiliary subunits that formulate the voltage-gated channel Ca2+ modulate

properties such as inactivation and channel targeting to the membrane (Gerster

et al., 1999). Voltage-gate Ca2+ channels also play a role in intracellular protein

phosphorylation and gene expression (Bading et al., 1993).

Astrocytes have many of the same signaling mechanistic pathways found

in neurons. Presence of voltage-gated ionic currents, neurotransmitter-gated
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ionic currents and receptor-activated intracellular second messenger systems

functions in neurons by means of extracellular chemical signals (Duffy et al.,
1994). Depolarization of acutely isolated astrocytes increases the intracellular

concentration of Ca2+, which indicates that Ca2+ influx may activate several

protein kinases (Quandt et al., 1986). Ca2+ influx causes astroglial depolarization
and plays a role in the common pathway in neuron-glial signaling during

pathology (Duffy et al., 1994). Functional significance of voltage-gated Ca2+

channels was confirmed through electrophysiological, pharmacological, and
physiological tests (Latour et al., 2003). Ca2+ voltage-gated possess many ways

of regulating cellular functions and homeostasis (Latour et al., 2003).
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2.

Hypothesis and Specific Aims

The hypothesis of the study is: Increasing cGMP depresses delayed rectifier

potassium (KDR) currents in astrocytes via cGMP-dependent phosphorylation,
which in turn improves normal synaptic neurotransmission.

Specific Aims

1. Measure membrane currents in astrocytes directly with the perforatedpatch, patch-clamp technique.

2. Identify the predominant K+ channels carrying outward current in
astrocytes.

3. Measure the effect of NO & cGMP on K+ currents in astrocytes.

4. Determine the primary molecular target (ion channel) of cGMP in these
cells.

5. Delineate cGMP signal transduction in astrocytes.
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3. Methods and Materials
I.

Cell Culture

Astrocytes were purchased from Neuromics. Astrocytes were received in

a vial along with hippocampal tissue. The vial was placed in a sterile hood for 15

min to allow all tissue and cells to settle to the bottom. Papain (digesting
solution) and Neurobasal media were placed in the incubator (5% CO2, 37°C,

humidified) for 30 min. One ml of medium was removed from the vial. Using a 1

ml pipettor and a sterile tip the tissue and remaining media was triturated in
the vial until all tissue was dispersed. All material from the vial was removed

and dispensed into the tube containing papain. The tube was then placed into
the incubator and gently shaken every 5 min for 30 min. The solution was
triturated again (10-15 times) then 1 ml of media was added to dilute the
digesting enzyme solution. The solution was triturated again (10-15 times). The
tube was then centrifuged at 1100 rpm for 1 min. The supernatant was removed

and the Neurobasal media (6 ml) was added to disperse the pellet. The solution

was triturated (10-15 times) and then the remaining 6 ml of Neurobasal was
added. The solution was triturated once more (10-15 times). The cells were

separated into 3 25cm2 poly-D-lysine coated flasks. Media (Neurobasal) was

changed every 2-3 days (5 ml per flask). Used poly-D-lysine coated flasks were
coated using a 100 μg/ml poly-D-lysine and 1X PBS coating solution over night.
Once the cells reached the proper confluence the media was removed and the
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cells were washed with 5 ml of 1X PBS. The PBS was removed and 0.5-1.0 ml of

0.25% Trysin-EDTA (1X) was added to each 25cm2 flask. The flask was placed in
the incubator for 5 min. The bottom of the flask was gently tapped to remove

the cells. Once all the cells detached from the flask 5 ml of Neurobasal was
added to the flask. The solution was triturated to mix the cells and neutralize
the trypsin. 5 ml of the cell solution was aliquot to 1-2 new 25cm2 flasks
(depending on the cell confluence before trypsinizing) and ~1ml of cell solution
was used for patch-clamp experimentation.
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II.

Perforated Patch-Clamp

Astrocyte cells were placed on the stage of an inverted microscope and

perfused at room temperature with artificial cerebrospinal fluid (aCSF) with the
following composition: NaCl 120mM; KCl 15mM; CaCl2 2; MgCl2 1mM; D-glucose

10mM; HEPES 10mM at pH 7.4. Patch pipettes are made using capillaries of
Corning Glass 7052 and the tip of the patch pipettes are filled with the following

solution in mM: 85 KCH3SO3, 30 KCl, 5 MgCl2, CaCl2 mM and 10 Hepes. The rest
of the patch pipette is back-filled with 200mg/ml amphotericin B. Amphotericin

B produces microperforations in the cell membrane isolated within the patch

pipette. These micropores provide electrical continuity between the pipette and
the cell, thus allowing voltage-clamping and recording of cellular currents. An

advantage of these micropores is that they are permeable to only monovalent
ions. Therefore, the cell is allowed to control and maintain its own physiological

calcium concentration as normal. In addition, important cellular signaling
molecules (e.g., cGMP, PKG) do not diffuse out of the cell during an experiment –
which occurs during standard whole-cell recording configurations. In summary,
perforated-patch recordings provide accurate current measurement with only

minimal current decay or loss of soluble cytoplasmic components due to

cellular dialysis. Furthermore, endogenous calcium buffering is not inactivated
by dialyzing cells with calcium chelators, as are required during traditional
whole-cell recordings. Thus, the perforated-patch technique provides a more
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accurate means of measuring whole-cell currents from a “metabolically-intact”
cell.

An Axopatch 200B amplifier was used to control voltage-clamp and

voltage-pulse generation and pCLAMP 9.2 software was used to acquire

(Clampex) and analyze (Clampfit) the data. After establishing a low-resistance

(<20MΩ) pathway for measuring cellular currents, as determined by amplifier
compensation circuitry, cells were voltage-clamped at a holding potential of -90

or -50mV, and membrane currents were recorded via Clampex 9.2 data

acquisition software. Drugs were added to the cell bath in various combinations
to effectively test for project objectives: tetraethylammonium (TEA), KDR

blocker; sodium nitroprusside, NO donor; 8Br-cGMP, membrane-permeable
cGMP derivative; KT5823, PKG inhibitor; forskolin, cAMP agonist. K+ currents

were measured through perforated, cell-attached patches in standard aCSF
solution.

Whole-cell currents were measured in response to a 500 msec

depolarizing test potential (-80 to +60mV) from a holding potential of either -90

or -50mV. Complete current (I) – voltage (V) relationships were constructed by

measuring the peak steady-state outward current at each test potential, and
these peak currents were then plotted as a function of membrane voltage.
Summary I-V relationships were normalized as current density (current

amplitude / cell capacitance) in order to account for possible variations in
current amplitude due to cell size.
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III.

Nitric Oxide Production Can Be Stimulated In Astrocytes

The following steps were followed for detection of nitric oxide

production in astrocytes. Astrocytes were split into 11 poly-D-lysine coated
wells of a 24-well plate. Incubated with 1 ml Neurobasal medium for 4 days

before experimentation. Neurobasal medium was removed and 1 ml of 2μM

DAF-FM 4-amino-5-methylamino-2’,7’-difluorofluorescein, DiaminofluorescienFM (DAF-FM; fluorophore detecting NO production; diluted in KREBS solution)

was added to 10 wells. Only KREBS solution was added to the 11th well for
control. Astrocytes were incubated for 45 min in the DAF-FM solution. After 45

min the DAF-FM solution was removed and 10μM sodium nitroprusside was

added to 6 of the 10 wells that were incubated with DAF-FM for 10 min.

Fluorescence was detected using the EVOS microscope GFP filter.
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Figure 4-1

Figure 4-1 A. Imaging of cells demonstrated typical astrocytic phenotype

under phase lighting. B. Same field of astrocytes loaded with DAF-FM and

treated with 10µM sodium nitroprusside (10 min). Green fluorescence indicates
production of nitric oxide in response to drug treatment.

Statistics
All data were expressed as the mean + S.E. Statistical significance between two

groups was evaluated by Student's t test for paired data. Comparison between
multiple groups was made by the One-Way Analysis of Variance test. A

probability of less than 0.05 was considered to indicate a significant difference.
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4. Results
I.

KDR Currents Dominate Membrane Electrical Activity In Astrocytes

There are 38 different voltage-gated K+ channel genes within the Kv

family. Eleven K+ channels are encoded as delayed rectifiers and 6 are encoded
for A-type channels (Smith et al., 2008). Thus, our first task was to employ
electrophysiological methods to directly identify the specific type(s) of K+

channels, which are expressed and functional in embryonic astrocytes. Wholecell recordings measured prominent outward currents (Figure 5-1). In contrast,
no significant inward currents were detected. From a holding potential of -

90mV, currents often exhibited a somewhat biphasic kinetic profile – rapid
activation, followed by a slower, more sustained steady-state component.
Subsequent analysis revealed this composite outward consisted of two
prominent outward currents: fast-activating/inactivating current, and a more

slowly activating, non-inactivating current. These currents were consistent with
astrocytic expression of the fast A-type potassium current, and the slower, but
sustained delayed rectifier (KDR) potassium current.

Because A-type currents inactivate fairly rapidly at depolarized

potentials, we were able to differentiate these 2 types of K currents by varying
the holding potential. Although A-type currents are fully activated by

depolarization from a holding potential of -90mV, voltage-clamping astrocytes

at a depolarized holding potential of -50mV largely inactivates A-currents. Thus
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by digitally subtracting the currents measured from Vhold = -50mV

(predominantly KDR currents) from the composite currents measured from Vhold

= -90mV, we were able to isolate the underlying A-type currents (as illustrated
in Figure 5-1) which contribute minimally to steady-state outward currents.

In addition to this biophysical analysis, we were able to differentiate

these distinct currents by pharmacological means. Tetraethylammonium (TEA;

3mM) is generally considered a non-selective K channel inhibitor, but KDR

channels are sensitive to low millimolar concentration of TEA. In contrast, A-

type currents are largely insensitive to TEA. We found that TEA attenuated
steady-state outward currents elicited from a Vhold of -50mV by >50% at the

peak of the I-V relation (+120 mV), and by an average of 37.0 + 0.5% at less
depolarized voltages (+100 mV; n=2). In contrast, TEA had little effect on A-type
currents (as revealed by the above subtraction protocol; Figure 5-2). Taken

together, these biophysical and pharmacological analyses indicate that both Atype and KDR potassium channels carry outward currents in astrocytes. Further,

these findings indicate that we are able to study KDR currents essentially in

isolation simply by employing a Vhold of -50mV (where A-type currents are
largely inactivated).
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Figure 5-1

Figure 5-1:

Biophysical identification of KDR and A-type potassium

currents in astrocytes. Top panel: Family of composite currents (-80 to

+120mV test potentials) elicited from a holding potential of -90mV. Each test
potential was a 500 msec depolarizing voltage step. Left panel: Family of
currents elicited from a holding potential of -50mV.

These currents were

carried predominantly via KDR channels because setting the holding potential to
depolarized voltages inactivates A-type currents. Right panel:

Family of

calculated test potentials generated by digitally subtracting KDR currents from
composite currents to reveal underlying A-type currents.
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KDR Currents

A-type Currents

Figure 5-2

Figure 5-2: Pharmacological characterization of potassium currents in
astrocytes. Left panel: Outward currents measured in astrocytes in response
to a +120mV test pulse from a Vhold of -50mV. Currents were recorded before

(con) and after a 15-min exposure to 3 mM tetraethylammonium (TEA). Right
panel: Calculated A-type outward currents from astrocytes in response to a
+120mV test pulse. Currents were recorded before (con) and after a 15-min
exposure to 3 mM tetraethylammonium (TEA).
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II.

Nitric Oxide Decreases KDR Currents In Astrocytes

There is increasing evidence that aging may alter how the brain

responds to NO, although the effects of NO on brain function remain
controversial. Moreover, little is known regarding how NO affects the ionic

mechanisms governing astrocyte excitability. To investigate this mechanism,
we treated astrocytes with sodium nitroprusside (SNP), which releases NO

when metabolized by cellular enzymes. As illustrated in Figure 5-3, treating
astrocytes with SNP reduced outward currents, carried mainly via KDR channels
(Vhold = -50mV), at all positive test voltages. On average, a 15-min exposure to
10 µM SNP reduced the density of KDR steady-state currents by 33 + 6% (+80mV

test potential; Vhold = -50mV; n=3 cells). A summary normalized current –

voltage relationship for several astrocytes, before and after SNP, is illustrated in
Figure 5-3.

To our knowledge, these findings provided the first direct evidence that

NO could depress KDR currents in astrocytes; however, signaling events
downstream from NO generation remained unknown. Because a primary target

of NO action is stimulation of soluble guanylyl cyclase to catalyze the generation
of cGMP from GTP, our next series of experiments tested the effects of cGMP on
KDR currents in astrocytes. Unfortunately, cGMP is essentially membrane

impermeable. To overcome this experimental limitation we employed a more
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permeable derivative, 8Br-cGMP, which diffuses across the plasma membrane
of astrocytes and stimulates cGMP signaling within these cells.
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Figure 5-2

Figure 5-3: Sodium nitroprusside (SNP; NO donor) reduces KDR in
astrocytes. (A) Membrane Currents (-80 to +120 mV; Vhold = -50 mV)

recorded from the same astrocyte before (control) and 15 min after exposure to
10 µM SNP. (B) Complete average current-voltage relationship for steady-state
outward currents as in A. Each point represents the mean of 3 cells + S.E. On

average, SNP decreased KDR current density by 33.3 + 6% (+80 mV). Proposed
signaling pathway for SNP / NO is illustrated to the right.
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III.

cGMP decreases KDR Currents In Astrocytes

As illustrated in Figure 5-4, increasing cGMP levels in astrocytes

depressed currents carried by KDR channels. Tracings provided in Figure 5-4A

are recorded from the same astrocyte (Vhold -50mV) before and after exposing

the cell to 500 µM 8Br-cGMP (20 min). Increasing intracellular cGMP levels
decreased steady-state outward currents at every test potential. On average,

8Br-cGMP decreased steady-state KDR currents 15 + 3% (+80mV; n=3). A

summary normalized current – voltage relationship of experiments from 3
astrocytes, before and after exposure to 8Br-cGMP is illustrated in Figure 5B.

Elevation of cellular cGMP levels is known to stimulate at least 3

prominent effector molecules in a variety of cell types:

cGMP-gated ion

channels, phosphodiesterases, and the cGMP-dependent protein kinase (PKG).
Previous studies from our laboratory had measured powerful effects of PKG on

outward potassium currents in vascular smooth muscle cells (White et al., 1995;

White et al., 2000). Because we had observed depression of potassium currents

by treating astrocytes with either NO or cGMP, we next tested the possibility

that cGMP was decreasing KDR currents in astrocytes via cGMP-dependent

phosphorylation mediated by PKG.
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Figure 5-3

Figure 5-4.

Elevating intracellular cGMP decreases KDR currents in

astrocytes. (A) Membrane currents (-80 to +120 mV; Vhold = -50 mV) recorded
from the same astrocyte before (control) and 20 min after exposure to 500 µM

8Br-cGMP, a membrane-permeable cGMP derivative. (B) Complete average
current density - voltage relationship for steady-state outward currents as in A.

Each point represents the mean of 3 cells + S.E. On average, 8Br-cGMP

decreased KDR current density by 15 + 3% (+80mV). Proposed signaling
pathway for cGMP is illustrated to the right.
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IV.
Inhibition of PKG attenuates cGMP-induced inhibition of KDR
currents

As expected, treating astrocytes with 500 µM 8Br-cGMP depressed

steady-state KDR currents in astrocytes (Figure 5-5). However, subsequent
cumulative addition of 300 nM KT5823, a selective inhibitor of PKG activity,
completely reversed the inhibitory effect of cGMP on outward currents.

Moreover, inhibition of PKG activity increased the amplitude of KDR currents

well above control levels. In fact, inhibition of PKG activity with KT5823 more

than doubled KDR currents at all test voltages. These findings not only identified

PKG as the primary downstream mediator of cGMP action on membrane

currents in astrocytes, but also strongly suggested that PKG exerts a tonic
suppression of KDR current under basal (non-stimulated) conditions – and thus
help maintain astrocyte excitability.

Experiments in other cell types had established that PKG, although

activated by cGMP preferentially, is not specific for cGMP alone.

In fact,

previous findings from our laboratory had demonstrated that cAMP can cross-

activate PKG and thereby modulate cellular potassium currents (White et al.,
2000; Zhu et al., 2002). Thus, it was possible that PKG activity in astrocytes
might also be stimulated by cAMP, another powerful and ubiquitous cellular
second messenger.
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Figure 5-4

Figure 5-5: Inhibiting PKG activity reverses the stimulatory effect of
cGMP on KDR currents in astrocytes. Top panel illustrates outward currents

recorded in the same astrocyte (Vhold -50mV) before (control), 20 min after 500
µM 8Br-cGMP, and then 30 min after further addition of 300nM KT5823 (a

selective PKG inhibitor). Not only did inhibition of PKG reverse the inhibitory
effect of cGMP, but KT5823 more than doubled outward currents in this cell.
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IV.

Cyclic AMP Decreases KDR Currents In Astrocytes

To test the possibility that cAMP might also suppress KDR currents in

astrocytes, we performed another series of experiments in which we generated
cAMP in these cells and measured outward currents. As illustrated in Figure 5-

6A, addition of 10 µM forskolin (20 min), a stimulator of adenylyl cyclase

activity, decreased outward currents in astrocytes at all test voltages. This
inhibitory effects was further illustrated by the summary current density –
voltage relationship for steady-state outward (KDR) currents in astrocytes. On

average, forskolin decreased KDR current density by 29.8 + 6% (+80mV; n=3
cells).

These findings strongly suggest that KDR currents in astrocytes are

regulated by both cGMP and cAMP; however, the signaling pathways

downstream from these nucleotides may then converge on a common effector
molecule, PKG, which mediates suppression of KDR currents most likely by

phosphorylation of KDR channels or a closely-associated regulatory protein.
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Figure 5-5

Figure 5-6. Elevation of cAMP depresses KDR currents in astrocytes.
(A)Membrane currents (-80 to +100 mV; Vhold = -50 mV) from the same
astrocyte before (control) and 20 min after exposure to 10 µM forskolin, a

cAMP agonist. (B) Complete summary current density-voltage relationship for
steady-state outward currents as in A. Each point represents the mean of 3 cells
+ S.E. On average, forskolin decreased KDR current density by 29.8 + 6% (+80
mV).
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6.

Discussion

The incidence of neurological disease is increasing, and yet there is no

cure for most diseases with debilitating loss of memory and brain function.

Astrocytes protect neuronal function, and are a possible therapeutic target for
helping to slow the progression of neurological diseases. However, we know

relatively little about the molecular basis of astrocyte protection in most

neurological diseases. Over the past decade there has been increasing evidence
that cGMP is an important secondary messenger in the brain and is modified by

different physiological and pathological conditions in certain areas of the brain.

Recent clinical trials indicate that phosphodiesterase inhibitors (e.g., sildenafil)
may improve learning and memory by increasing the levels of cGMP in the
brain, as does increasing levels of nitric oxide. But at the present time, the

mechanisms whereby the NO/cGMP/PKG signaling pathway can help alleviate

memory loss and cognitive function are unknown. Our findings suggest that
increases in cGMP via nitric oxide signaling depress steady-state outward

potassium currents in astrocytes via cGMP-dependent phosphorylation

mediated by PKG. We believe this mechanism helps to improve normal synaptic
neurotransmission. Through electrophysiology, using the perforated whole-cell

patch clamp technique, we have identified a potential novel target of cGMP

action in astrocytes: the delayed-rectifier potassium (KDR) channel.

Astrocytes exhibit inward currents via sodium channels and both inward

and outward currents via potassium channels; however, these cells do not
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propagate action potentials (Sofroniew et al., 2010). Nonetheless, astrocytes are
excitable via regulated increases in intracellular calcium concentrations.
Evidence shows that increases in intracellular calcium are of functional
significance

in

astrocyte-astrocyte

and

astrocyte-neuron

intercellular

communication (Sofroniew et al., 2010). Increases in cytosolic calcium

concentrations can result from the release of intracellular calcium stores,

neurotransmitters released during neuronal activity, or by propagation of
signals from neighboring astrocytes (Sofroniew et al., 2010). Astrocytes envelop

all synapses, provide essential functions that maintain the homeostasis of
synaptic transmission, and play direct roles in synaptic transmission through

the release of gliotransmitters in response to neuronal synaptic activity.

(Sonfroniew et al., 2010). Astrocytic mechanisms exert powerful influences on
synaptic remodeling in the CNS or in response to CNS disorders (Sofroniew et

al., 2010).

Gliotransmitters are released in response to astrocytic excitability via

increases in intracellular calcium concentrations. Astrocytes express L-type
calcium channels, which exhibit an activation threshold of approximately -35mV

(Bijlani et al., 2010). Thus, relatively small depolarizing stimuli can enhance

calcium channel opening and stimulate astrocyte excitation and release of
gliotransmitters. In addition to calcium channels, potassium channels exert a

powerful influence upon astrocyte membrane potential, and as such are a major
regulatory influence upon calcium channel gating. Astrocytes express several

species of voltage-dependent potassium channels, with KDR being a prominent
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example. Depolarization increases the activity of KDR channels, and their

repolarizing influence serves as a “brake” on cellular activity by closing voltage-

dependent calcium channels and thereby depressing gliotransmission.
Conversely, any agent that decreases currents through KDR channels (e.g.,
neurotransmitters, second messengers, drugs) would tend to enhance cellular
depolarization, and thereby stimulate gliotransmission.

NO is a liposoluble gaseous molecule which readily passes through the

cellular membrane. NOS are the enzymes responsible for the formation of NO,

and exist in three isoforms: iNOS, eNOS, nNOS. NO is involved in almost all
processes of neuronal transmission due to the ubiquitous distribution of NOS

throughout the brain, where its primary function is to activate sGC. sGC when

activated by NO catalyzes the conversion of GMP to cGMP, which in turn

activates PKG. It is PKG that functions as a primary molecular effector by
phosphorylating a variety of signaling substrate molecules in the brain, and
thereby modifying their function. PKG is known to be a critical factor during
synaptic plasticity. Therefore, increases of NO via NOS lead to increases of

intracellular cGMP and PKG activity, and thereby likely modulate synaptic
plasticity.

Much research has been focused on cGMP due to its ability to improve

memory and cognitive function. For example, a recent and promising
therapeutic development is the use of PDE inhibitors to enhance memory by

increasing cGMP levels in the brain. The NO/cGMP pathway is the one of the

physiological mediums for producing cGMP in the cell, yet our understanding of
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how NO/cGMP modulates excitability of neurons and astrocytes is minimal, at
best. To help address this gap in our knowledge, we measured the effects of
NO/cGMP on cellular currents in astrocytes directly. We initially elevated NO
levels in isolated astrocytes by administering sodium nitroprusside, which

releases NO as it is metabolized by cells. Our findings demonstrated that NO

depressed outward potassium currents carried predominately via the KDR

channel. This depression of KDR current would suppress efflux of potassium

ions, thereby exerting a depolarizing (excitatory) influence on astrocyte activity.
Thus, NO would promote depolarization-stimulated increased calcium

accumulation and enhanced excitability. Since cGMP production is a
downstream effector of NO, our next question was: Would adding cGMP directly

mimic the effect of NO on KDR?

cGMP plays a role in the biochemical cascade that regulates cognitive

functions, and is assumed to mediate the positive therapeutic effect of PDE

inhibitors. PDEs regulate cyclic nucleotide (cGMP and/or cAMP) signaling by

metabolizing and inactivating these powerful intracellular second messengers
(Zhihui et al., 2013). Thus, PDE inhibitors increase cellular cGMP
concentrations, but do so independent of NO generation (Zhihui et al., 2013).

PDE inhibitors increase cGMP concentrations, which may trigger downstream
phosphorylation via PKG.

Studies have shown that aging increases PDE expression and decreases

cGMP concentrations in the brain (Zhihui et al., 2013). There is also substantial
evidence that cGMP plays a part in signaling cascades that are important for
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learning and memory. Recent studies imply that long-term memory may be

enhanced significantly in patients given cGMP-targeting PDE inhibitors (Bollen

et al., 2014). cGMP-specific PDE inhibitors serve as a modulatory function for

memory and synaptic plasticity. Development of specific PDE inhibitors has
been suggested as novel therapeutic targets for certain neurological diseases
that cause loss of memory and cognitive function. However, the mechanistic
action for how this is accomplished is not understood.

Our findings now

provide evidence for a novel cellular mechanism that could potentially account
for the therapeutic effect of PDE inhibitors on memory: depression of KDR

currents leading to enhanced excitation of astrocytes (and possibly neurons as
well).

It is of importance to determine the effects of increased intracellular

cGMP concentrations on KDR to further our understanding of the mechanism of
how NO/cGMP/PKG signaling enhances learning, memory, and cognitive

function. 4 did in fact depress KDR currents. These findings remain consistent

with our hypothesis, and were confirmed by our findings that increasing NO
depressed KDR in astrocytes. Although the direct effect of cGMP (i.e., 8Br-cGMP)
on KDR currents was not as robust as the effect of sodium nitroprusside (Figure

6), this difference is likely related to the difficulty of cGMP to permeate the cell
membrane – unlike NO, which generates cGMP within astrocytes more directly

via activation of sGC. Nonetheless, the depression of KDR was statistically
significant and important to the overall findings. The data clearly demonstrate
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that raising intracellular concentrations of cGMP either directly with 8Br-cGMP

or indirectly with NO decreases KDR in embryonic astrocytes.

Most researchers believe that object memory and cognitive function are

dependent on cGMP-dependent phosphorylation (i.e., PKG activity) in the

hippocampus. Indeed, studies suggest that cGMP and PKG may facilitate

memory formation and synaptic plasticity (Bollen et al., 2014). Interestingly,

cGMP-PKG signaling has shown to act as a modulatory system that increases

Ca2+ in neurons. We believe that this same signaling system may intrinsically

modulate Ca2+ influx in astrocytes, and propose that depression of KDR currents

may be an important mechanism that produces this response.

Previous studies suggest that elevated levels of cGMP and PKG can lower

stimulation threshold for Ca2+ signals (Bollen et al., 2014). However, the

mechanism for how this is done is not understood. To test our hypothesis that
PKG mediated the inhibitory effect of NO/cGMP on KDR currents, we employed
an antagonist (KT5823) that exhibits high selectivity for PKG. Our findings

clearly demonstrated that inhibition of PKG activity attenuated the inhibitory
effect of cGMP on KDR, thus indicating that PKG-mediated phosphorylation

depresses activity of KDR channels in embryonic astrocytes. Somewhat
surprisingly, KT5823 increased the amplitude of outward far above basal levels,

suggesting that PKG likely exerts a tonic inhibitory influence on KDR currents

even under non-stimulated conditions. As discussed above, this inhibitory

influence of PKG on potassium efflux – during stimulated or non-stimulated

conditions -- would help maintain astrocyte depolarization, prolong calcium
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influx, and thereby stimulate gliotransmission – leading to enhanced synaptic

plasticity. In sum, we propose that cGMP-dependent phosphorylation is an
important intrinsic signaling mechanism that enhances synaptic plasticity,

memory and cognitive function via inhibition of the KDR currents. Further, these

findings suggest that KDR channels and cGMP signaling molecules are likely to be
powerful therapeutic targets for helping to treat Alzheimer’s and possibly other
debilitating neurological diseases.

To our knowledge, these findings are the first to demonstrate an

inhibitory effect of PKG on KDR currents in astrocytes, and are supported by

previous studies indicating that PKG-mediated phosphorylation modulates KDR

currents in other cell types. For example, Shimuzi et al. (2002) suggested that

KDR is decreased by PKG in guinea-pig sinoatrial (SA) node cells. In addition, Xu

et al. (2008) found that 8-Br-cGMP inhibited KDR in both hypoxic and normal rat

pulmonary artery smooth muscle cells. As we found in astrocytes, inhibition of

PKG with KT5823 completely blocked the inhibition of KDR via 8-Br-cGMP in

these muscle cells. Thus, it was suggested that the effect of cGMP on KDR is
mediated by PKG-dependent phosphorylation of the channel. At present it is
unknown whether the KDR channel protein is the actual substrate for PKGdependent phosphorylation, or whether PKG might instead phosphorylate a

closely-associated regulatory protein. However, it is speculated that
phosphorylation of KDR channel proteins by PKG might alter the voltagesensitivity of the channel (Shimuzi et al. 2002).

KDR possesses four

phosphorylation sites for the cAMP-dependent kinase (PKA), and exhibits cyclic
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nucleotide binding domains in the C-terminal that can be modulated via the

cAMP-PKA phosphorylation pathway in guinea pig ventricular myocytes (Xu et

al., 2008). Because PKG, like PKA, is a serine-threonine kinase, it is possible that

similar consensus phosphorylation sites for PKG exist on the KDR channel

protein; however, future studies are needed to identify these putative PKG
phosphorylation sites on KDR. Of note, we also found that increasing cAMP levels
in astrocytes (via forskolin) decreased KDR currents, quite possibly via cross-

activation of PKG. Although a potential role for PKA in astrocyte excitability has

not yet been established, elevating cAMP by treatment with the PDE inhibitor
rolipram enhanced synaptic and cognitive function in a mouse model of AD

(Gong et al., 2004.). Thus, it is apparent that elevation of cyclic nucleotide levels
(either cGMP or cAMP) is a promising treatment for AD and possibly other

disorders of memory and cognition. Our findings are the first to propose a single
unifying signaling mechanism where by both cyclic nucleotides may act to
enhance brain function: phosphorylation of KDR channels in astrocytes via

activity of the cGMP-dependent protein kinase.
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6. Conclusion and Future Studies

Our research demonstrates that currents through KDR channels dominate

membrane electrical activity in embryonic astrocytes. We found that NO/cGMP
signaling depresses these KDR currents, and that the effects of NO/cGMP are
likely mediated by cGMP-dependent phosphorylation of the KDR channel (or a

closely-associated regulatory protein). This depolarizing effect would prolong
opening of voltage-dependent, L-type calcium channels to elevate astrocyte

calcium levels and enhance gliotransmission. Increased gliotransmission would
be likely to enhance synaptic plasticity, which may lead to improved memory
and cognitive function. These findings thus provide the first evidence for a

potential molecular mechanism that could now explain the beneficial effect of
PDE inhibitors and other cGMP–enhancing agents on learning and memory.

Though important, a limitation of these studies is that they consist of

electrophysiological studies of embryonic astrocytes. Future studies are needed
to examine the effects of enhanced cGMP-dependent phosphorylation of the KDR

via PKG in adult astrocytes. Future electrophysiologic studies will also be

needed to explore potential effects of increased intracellular concentrations of
cGMP on L-type calcium channels in adult astrocytes to ensure that the

phosphorylation of KDR channels is indeed causing calcium channels to open and

remain open to cause gliotransmission via astrocytic excitability.
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